Clinical Pharmacokinetic and Pharmacodynamic Profile of Vericiguat

[1]  R. Burghaus,et al.  Applied physiologically‐based pharmacokinetic modeling to assess uridine diphosphate‐glucuronosyltransferase‐mediated drug–drug interactions for Vericiguat , 2023, CPT: pharmacometrics & systems pharmacology.

[2]  M. Boettcher,et al.  Authors’ Reply to Ganijee et al.: “Comment on: Evaluation of the Influence of Sildenafil on Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Vericiguat in Healthy Adults” , 2023, Clinical Pharmacokinetics.

[3]  A. Solms,et al.  Assessing QTc Effects of Vericiguat Using Two Different Concentration-QTc Modeling Approaches , 2023, Clinical Pharmacokinetics.

[4]  Rupesh P. Amin,et al.  Nonclinical Cardiovascular Assessment of the Soluble Guanylate Cyclase Stimulator Vericiguat , 2023, The Journal of Pharmacology and Experimental Therapeutics.

[5]  M. Boettcher,et al.  Evaluation of the Influence of Sildenafil on the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Vericiguat in Healthy Adults , 2023, Clinical Pharmacokinetics.

[6]  Rizwan Kalani,et al.  Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association , 2023, Circulation.

[7]  D. Trenk,et al.  Vericiguat: A Randomized, Phase Ib, Placebo-Controlled, Double-Blind, QTc Interval Study in Patients with Chronic Coronary Syndromes , 2023, American Journal of Cardiovascular Drugs.

[8]  M. Boettcher,et al.  Results from in vitro and in vivo studies evaluating the bioavailability, effects of food, and administration as crushed tablet suspension on vericiguat pharmacokinetics , 2022, AAPS Open.

[9]  P. Armstrong,et al.  Sequential Evaluation of NT-proBNP in Heart Failure: Insights Into Clinical Outcomes and Efficacy of Vericiguat. , 2022, JACC. Heart failure.

[10]  A. Cohen-Solal,et al.  Vericiguat and NT‐proBNP in patients with heart failure with reduced ejection fraction: analyses from the VICTORIA trial , 2022, ESC heart failure.

[11]  F. Gheyas,et al.  Population Pharmacokinetics of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: An Integrated Analysis , 2022, Clinical pharmacology and therapeutics.

[12]  P. Armstrong,et al.  Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial , 2022, European journal of heart failure.

[13]  S. Sandmann,et al.  Pharmacokinetics and mass balance of vericiguat in rats and dogs and distribution in rats , 2022, Xenobiotica; the fate of foreign compounds in biological systems.

[14]  M. Link,et al.  2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. , 2022, Circulation.

[15]  D. Trenk,et al.  Vericiguat in combination with isosorbide mononitrate in patients with chronic coronary syndromes: The randomized, phase Ib, VISOR study , 2022, Clinical and translational science.

[16]  G. Mikus,et al.  Vericiguat in Combination with Short‐Acting Nitroglycerin in Patients With Chronic Coronary Syndromes: The Randomized, Phase Ib, VENICE Study , 2022, Clinical pharmacology and therapeutics.

[17]  K. Anstrom,et al.  Blood Pressure and Safety Events With Vericiguat in the VICTORIA Trial , 2021, Journal of the American Heart Association.

[18]  J. Stasch,et al.  Soluble guanylate cyclase stimulators and activators: Past, present and future. , 2021, British journal of pharmacology.

[19]  A. Solms,et al.  A concentration-QTc analysis of vericiguat , 2021, European Heart Journal.

[20]  J. Lippert,et al.  Leveraging translational approaches for accelerated clinical development of vericiguat , 2021, European Heart Journal.

[21]  C. Maschke,et al.  Vericiguat: a QTc interval study in patients with coronary artery disease , 2021, European Heart Journal.

[22]  J. McMurray,et al.  2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. , 2021, European heart journal.

[23]  B. Pieske,et al.  Population Pharmacokinetics and Pharmacodynamics of Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction , 2021, Clinical Pharmacokinetics.

[24]  Landkreis Freyung-Grafenau.  Bayer , 2021, Outlooks on Pest Management.

[25]  B. Ploeger,et al.  NT‐proBNP Qualifies as a Surrogate for Clinical End Points in Heart Failure , 2021, Clinical pharmacology and therapeutics.

[26]  M. Boettcher,et al.  Vericiguat clinical pharmacology programme: biopharmaceutical properties and potential intrinsic and extrinsic factor effects , 2020 .

[27]  M. Boettcher,et al.  Safety, pharmacodynamic, and pharmacokinetic characterization of vericiguat: results from six phase I studies in healthy subjects , 2020, European Journal of Clinical Pharmacology.

[28]  M. Boettcher,et al.  Pharmacodynamic and Pharmacokinetic Interaction Profile of Vericiguat: Results from Three Randomized Phase I Studies in Healthy Volunteers , 2020, Clinical Pharmacokinetics.

[29]  M. Radtke,et al.  Metabolism and Pharmacokinetic Drug–Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies , 2020, Clinical Pharmacokinetics.

[30]  P. Ponikowski,et al.  Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. , 2020, The New England journal of medicine.

[31]  K. Anstrom,et al.  Comparing the Benefit Of Novel Therapies Across Clinical Trials: Insights from the VICTORIA Trial. , 2020, Circulation.

[32]  U. Broeckel,et al.  Age‐ and Genotype‐Dependent Variability in the Protein Abundance and Activity of Six Major Uridine Diphosphate‐Glucuronosyltransferases in Human Liver , 2018, Clinical pharmacology and therapeutics.

[33]  P. Armstrong,et al.  Exploring New Cardiovascular Pathways: Are Soluble Guanylate Cyclase Stimulators the Right Direction? , 2018, Circulation. Heart failure.

[34]  Georg Ferber,et al.  Scientific white paper on concentration-QTc modeling , 2017, Journal of Pharmacokinetics and Pharmacodynamics.

[35]  P. Ponikowski,et al.  A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial. , 2017, JACC. Heart failure.

[36]  H. Trübel,et al.  Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure. , 2017, Journal of medicinal chemistry.

[37]  Sanjiv J. Shah,et al.  Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study , 2017, European heart journal.

[38]  Gianluigi Savarese,et al.  Global Public Health Burden of Heart Failure. , 2016, Cardiac failure review.

[39]  Sanjiv J. Shah,et al.  Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial. , 2015, JAMA.

[40]  C. Guillemette,et al.  Quantitative Profiling of Human Renal UDP-glucuronosyltransferases and Glucuronidation Activity: A Comparison of Normal and Tumoral Kidney Tissues , 2015, Drug Metabolism and Disposition.

[41]  Sanjiv J. Shah,et al.  Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES) , 2014, European journal of heart failure.

[42]  M. Volpe,et al.  Polypharmacy in Heart Failure Patients , 2014, Current Heart Failure Reports.

[43]  Xiaoping Du,et al.  Biphasic roles for soluble guanylyl cyclase (sGC) in platelet activation. , 2011, Blood.

[44]  R. Gerzer,et al.  NO-independent regulatory site of direct sGC stimulators like YC-1 and BAY 41-2272 , 2001, BMC pharmacology.

[45]  Lothar Roessig,et al.  Novel sGC Stimulators and sGC Activators for the Treatment of Heart Failure. , 2017, Handbook of experimental pharmacology.

[46]  R. Gerzer,et al.  Purified soluble guanylyl cyclase expressed in a baculovirus/Sf9 system: stimulation by YC-1, nitric oxide, and carbon monoxide , 1999, Journal of Molecular Medicine.